Economic loss from infection with bovine viral diarrhea virus (BVDV) is of worldwide concern. The unique pathogenesis and antigenic variability of BVDV have made this virus challenging to control. Vaccination programs are a major component of control and prevention strategies. Both killed and modified live vaccines are commercially available. Choice between killed and modified live vaccines is controversial. Of major concern is the safety of modified live vaccines. Little information is available on their tissue tropism and potential for causing pathology, especially with respect to the reproductive system. The objective of this study was to determine if BVDV could be detected in the ovary of cattle following immunization with a modified live BVDV vaccine. In 2 separate trials, 6 heifers and 4 mature cows were immunized with a modified live BVDV vaccine and ovaries were removed between 7 and 30 days postvaccination. Cytopathic BVDV was isolated from ovaries removed on days 8, 10, and 12. BVDV antigen was detected using immunohistochemistry on days 10-30. These findings are significant because replication of virus in the ovary could cause ovarian dysfunction, resulting in reduced fertility.
Bovine viral diarrhea virus (BVDV) is one of the most important viral pathogens of cattle, 2,7 and its control and prevention are of worldwide concern. Because of its complex pathogenesis and antigenic diversity, control and prevention of BVDV infections has been extremely challenging. Control programs center around elimination of cattle persistently infected with BVDV, biosecurity, and vaccination. 2, 7 The role of vaccinations in the prevention of BVDV has become extremely controversial. Much of the debate revolves around the use of modified live or killed BVDV vaccines. Modified live BVDV vaccines have been available since 1961. 6 Currently, these vaccines use cytopathic BVDV strains, which have been attenuated through multiple cell culture passage. 4 It is generally felt that modified live vaccines provide higher levels of protective immunity that are of longer duration. 2, 4 However, the safety of these vaccines is of concern. 2, 10 Postvaccination mucosal disease, 16, 20 immunosuppression, 21 and fetal infection resulting in abortion and congenital anomalies 14, 23 have been reported following modified live BVDV vaccination. Also, disease resulting from the contamination of modified live vaccines with noncytopathic BVDV strains has been reported. 12, 13 With in vivo replication of vaccine virus, the potential exists for viral mutations, resulting in increased virulence. 4 Safety is the major advantage of killed BVDV vaccines. However, the need for 2 initial doses of vaccine to stimulate a primary immune response and the apparent short duration of protective immunity are the major disadvantages of these vaccines. 4 Reproductive pathology resulting from acute infection with BVDV is well documented. Poor conception rates, early embryonic deaths, abortions, various congenital defects, and the establishment of persistent BVDV infection in the gestating fetus have all been reported. 18 The cause of reduced fertility in cattle with acute BVDV infection is unclear. Little is known about the effects BVDV may have on the ovary following acute infection and the role this may play in reducing fertility. BVDV has been isolated from the ovary following experimental acute infection 22 and from ovaries collected from abattoirs. 3 Oophoritis has also been described following acute BVDV infection. 22 BVDV infection has been suggested as a cause of ovarian dysfunction, but few studies have been conducted to examine this possibility. 15, 22 In cattle being superovulated while undergoing acute BVDV infection, a significant reduction in the number of palpable corpus lutea and recovered embryos has been reported. 11 In cattle persistently infected with BVDV, a reduction in the number of antral follicles is evident. 8 These studies suggest that BVDV infection may affect follicular dynamics. To date, there are no reports of virus isolation or ovarian pathology following immunization with modified live BVDV vaccines. The objective of this study was to determine if BVDV could be isolated or identified in the ovary following modified live BVDV immunization.
Materials and methods
Two separate trials were conducted. In trial A, 6 pubertal Angus heifers were determined to be BVDV negative by virus isolation and BVDV seronegative by virus neutralization. Each heifer was immunized with a commercially available multivalent vaccine containing modified live BVDV, infectious bovine rhinotracheitis virus, bovine respiratory syncytial virus, and parainfluenza-3 virus. The cattle were isolated for the entire length of the study. Necropsies were performed on 2 animals each on days 8, 10, and 12 postvaccination. Sections of ovaries, oviduct, uterus, kidney, Peyer's patch, liver, jejunal and bronchial lymph node, thymus, and tonsil were collected for virus isolation. Whole blood and nasal swab samples were taken daily to monitor for viremia. In trial B, 4 BVDV-seronegative and BVDVnegative Holstein cows were vaccinated with the same vaccine but from a different lot than was used in trial A. The cows were kept isolated for the length of the study. Whole blood samples were taken daily to monitor for viremia. Unilateral ovariectomies were performed on 2 cows at 7 and 10 days postvaccination. A second ovariectomy was performed on the same cows on days 20 and 30 postvaccination. Sections of ovary were processed for virus isolation, histology, and immunohistochemistry.
White blood cells were isolated from whole blood samples following hypotonic lysis of red blood cells with a 0.83% solution of ammonium chloride in distilled water. The cells were washed once with 10 ml of Dullbecco's modified Eagle medium a (DMEM), resuspended in 1 ml of DMEM, and then frozen at Ϫ70 C to lyse the white blood cells. Nasal swabs were placed in 4 ml of DMEM containing penicillin (100 units/ml), streptomycin (100 g/ml), and amphotericin-B (2.5 g/ml) and then vortexed. One gram of each tissue sample was homogenized in 4 ml of DMEM containing the same antimicrobials. The homogenate was then clarified by centrifugation, and the supernate was removed. Virus isolation was performed by inoculating 200-l samples of white blood cells, nasal swab supernate, or tissue homogenate supernate onto low-passage bovine turbinate cells in 24-well flat-bottom cell culture plates. Cells were passaged 3 times. Plates were observed daily for evidence of cytopathology and then stained after 5 days using a BVDV-specific immunoperoxidase test as previously described. 1 Samples of reconstituted vaccine were also subject to virus isolation to verify the presence of cytopathic BVDV.
Ovaries obtained during trial B were fixed in zinc formalin for 48 hr and then processed for routine paraffin embedment. Sections were processed for routine histologic staining with hematoxylin and eosin. Immunohistochemical procedures used were modified from those previously described. 9 Fivemicrometer sections were mounted on silane-treated slides and baked for 1 hr at 56 C. Sections were deparaffinized in a limonene-based solvent b for 15 min and then rehydrated through a graded series of ethanol solutions to distilled water. Endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide in absolute methanol for 5 min. Tissues were digested for 15 min at 37 C in 0.1% Protease XIV. c Following digestion, slides were washed in distilled water and then incubated with 5% horse serum in 0.05 M Tris buffer (blocking solution) for 30 min at 37 C to block nonspecific antibody binding. BVDV antigen was detected using the BVDV monoclonal antibody (MAb) 15C5 d in conjunction with an indirect avidin-biotin-peroxidase detection system (ABC). e MAb 15C5 was diluted 1: 1,500 in blocking solution and applied to the tissues for 30 min at 37 C. To remove unbound primary antibody, slides were washed in 0.25 M Tris buffer with 0.35 M NaCl and 0.0005% Triton-X. After washing, tissues were incubated with biotinylated horse anti-mouse IgG for 20 min at 37 C. Following washing to remove unbound secondary antibody, the ABC reagent was prepared as recommended by the manufacturer and incubated with the tissues for 20 min at 37 C. Removal of unbound ABC was followed by incubation with the substrate 3-amino-9-ethyl carbazole f for 10 min at room temperature. Sections were counterstained with Mayer's hematoxylin and coverslipped using an aqueous mounting medium. To detect nonspecific binding, the primary MAb was replaced with a similar concentration of an irrelevant MAb of the same isotype directed against infectious bursal disease virus. g Sections of ovary from cows persistently infected with BVDV and cows not infected with BVDV based on virus isolation and serology were processed as described previously and used as positive and negative controls, respectively.
Results
In trial A, cytopathic BVDV was isolated from the white blood cells of 3 of 6 heifers between days 6 and 10 postvaccination (Table 1) . BVDV was isolated from the blood of only 1 heifer (no. 99) at necropsy. No virus was isolated from nasal swabs. Cytopathic BVDV was isolated from the spleen of 1 heifer, thymus and tonsil of 2 heifers, and Peyer's patch of 3 heifers. Cytopathic BVDV was isolated from the ovaries removed on days 8, 10, and 12 postvaccination from 3 heifers ( Table 2) .
In trial B, no cytopathic or noncytopathic BVDV was isolated from white blood cells following immunization. Cytopathic BVDV was isolated from the ovary of 1 cow on day 10 postvaccination. BVDV antigen was detected in all ovarian sections taken on days 10, 20, and 30 postvaccination ( Table 3 ). The greatest amount of immunostaining was observed in ovaries taken on day 20. Immunostaining involved stromal and macrophage-like cells located in the cortical region of the ovary (Fig. 1) . Scattered accumulations of interstitial lymphocytes were observed starting at day 7 postvaccination and increasing in prominence by day 10 postvaccination. Focal lymphocytic infiltrates remained evident at 20 days and were minimal by day 30 postvaccination. Scattered eosinophils and rare neutrophils were observed in association with the lymphocytic infiltrates. Stromal vacuolation suggestive of edema was observed from day 7 to day 20 but was most severe at day 10 postvaccination. Focal lymphocytic infiltration of the corpus luteum was observed in 1 ovary removed at day 10 postvaccination.
Samples of reconstituted vaccine from both trials were cytopathic in cell culture and positive for BVDV antigen by immunoperoxidase assay.
Discussion
All current commercially available modified live BVDV vaccines are made from attenuated cytopathic BVDV. 4 The attenuation process is aimed at altering the virus so that replication is restricted in vivo. By doing this, virulence and shedding of the virus is reduced. It is known that vaccine virus can cross the placenta in gestating cattle, resulting in fetal pathology. 14, 23 For this reason, modified live BVDV vaccines are not recommended for use in pregnant cattle.
Cytopathic BVDV has been isolated from the bovine ovary following experimental infection and has been associated with prolonged oophoritis. 22 The isolation of BVDV from the ovary following vaccination with a modified live BVDV vaccine has not been reported. In this study, cytopathic BVDV was isolated from the ovaries of 4 animals between days 8 and 12 following immunization with a modified live BVDV vaccine. Isolation of BVDV during this period of time period is consistent with experimental challenge studies where both cytopathic and noncytopathic BVDV have been isolated between 5 and 15 days postinfection. 19, 22, 25 Given the time frame of virus isolation, the cytopathic nature of the virus, and the lack of exposure to other BVDV sources, it is likely that the isolated virus was of vaccine origin.
In trial A, cytopathic BVDV was isolated from various lymphoid tissues in the same 2 heifers in which BVDV was found in the ovaries. This finding is consistent with the lymphoid tissue tropism of BVDV. 5 In trial B, BVDV antigen was detected in ovarian sections by immunohistochemistry up to 30 days postvaccination. The histologic evidence of oophoritis was similar to that previously described following infection with cytopathic BVDV. 22 Although the inflammatory changes were similar to previous observations, the cause of the lesions cannot be solely attributed to the modified live cytopathic BVDV because of the presence of modified live infectious bovine rhinotracheitis virus in the vaccine, which has been documented to cause oophoritis. 24 The isolation of BVDV from the ovary following immunization with a modified live vaccine may be of significance if ovarian function is changed. Any functional changes may result in reduced fertility, which are of concern given that commonly recommended BVDV control and prevention strategies often involve the use of modified live BVDV vaccines near the time of breeding. 4 Vaccine-derived BVDV located in the ovary may have no effect on fertility. However, even modest reductions in fertility as a result of poor ovarian function may be significant from an economic standpoint. Modified infectious bovine rhinotracheitis virus used in commercial vaccines can cause luteal necrosis and oophoritis, which can result in short-term changes in ovarian function. 17 No controlled studies have been conducted looking at the fertility of cattle immediately following vaccination with BVDV. Additionally, this study was done in seronegative heifers. Virus replication in the ovary following modified live BVDV vaccination may not occur in seropositive cat-tle. If cattle are seropositive by the time they reach breeding age, vaccination with modified live vaccines may have no effect on the ovaries of these animals.
This study demonstrated that BVDV can be isolated from the ovaries of seronegative heifers following immunization with a modified live vaccine. The potential for causing ovarian dysfunction and reduced fertility is unknown. However, this possibility should be considered when designing vaccine protocols for breeding age cattle.
